The US Food and Drug Administration (FDA) has approved Eli Lilly’s anti-amyloid donanemab (Kisunla) 350 mg/20 mL once-monthly injection for intravenous infusion for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease with confirmed amyloid pathology. …
